The non-invasive solution for comprehensive management of liver health
FibroScan® is powered by three unique, patented and validated biomarkers to quickly and easily assess liver health.
Our solutions enable non-invasive diagnosis and monitoring at the point-of-care.
A painless exam performed in less than 4 minutes to provide immediate results at the point-of-care.
Can be performed by any trained operator (physician, nurse, medical assistant).
The non-invasive solution validated by 4,200+ peer-reviewed publications and 180+ international guidelines.
Standardized examination with exceptional precision and reproducibility that can be utilized in 99% of patients
Equipped with patented technology and proprietary algorithms to deliver consistently accurate results.
LSM by VCTE™ for liver fibrosis assessment
CAP™ for liver steatosis assessment
SSM by VCTE™ for portal hypertension assessment and variceal surveillance*
Ideal point-of-care solution for large sized and community hospital-based settings
Ideal point-of-care solution for private practice or office-based settings
Ideal point-of-care solution for high-volume hospital-based settings
Ideal point-of-care solution for primary care and endocrinology in office-based settings
Cloud-based solution to assist clinicians in providing comprehensive liver care.
Optimize clinical workflows with real-time secure data transmission
Enhance FibroScan® liver disease assessment with biological markers
*SSM is a marker for non-invasive evaluation of spleen stiffness which has been used in a clinical setting to assess portal hypertension and for variceal surveillance.
The FibroScan® device (Models: 502 Touch, 530 Compact, 430 Mini+, 230, and 630) is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography™ (VCTE™) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP™)* at 3.5 MHz. FibroScan® 630 Expert is also intended to measure spleen stiffness using VCTE™ at 100 Hz shear wave frequency. FibroScan® liver stiffness measurements (LSM) by VCTE™ may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan® CAP™ measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid for the clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided. *CAP™ refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP™ on S+ probe is only available with SmartExam capability.
FibroScan®
